Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

U.K.'s Cost Regulator Wants Allergan To Compare Ozurdex With Avastin In Macular Edema

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

NICE says it is "minded" to reject Allergan's Ozurdex but might be persuaded it is stacks up well against off-label Avastin use.

You may also be interested in...



NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day

Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.

NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day

Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.

U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal

NICE's preliminary rejection of Lucentis for macular edema paves the way for cheaper Avastin to swallow up most of the U.K. market.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS071920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By